• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

EGFR - Articles and news items

Prof Klaus Dugi, Corporate Senior Vice President Medicine, Boehringer Ingelheim

FDA approves Gilotrif™ (afatinib) as first-line treatment for lung cancer patients with EGFR mutations

Industry news, News / 16 July 2013 / Boehringer Ingelheim

First approval for afatinib, the frontrunner from Boehringer Ingelheim’s new oncology pipeline…

Gene to drugs: can expression be the key to new discoveries?

Genomics, Issue 1 2013 / 25 February 2013 / Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky

Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new strategies that will yield novel, long-lasting therapies and methods to rationally utilise existing therapies, alone and in combination, to individualise treatment regimens. The search for novel anti-cancer therapeutics or novel uses for existing drugs can benefit from the maturity of pharmacogenomics to extract genomic information for identification of new targets and therapeutic strategies.